TCR-Based Therapies Summit on April 01-03, 2025 in Boston, United States

2024 was pivotal for TCR therapies. Following the commercial approval for Adaptimmune's Tecelra, positive clinical readouts, and FIH trials from Immatics, Triumvira, Affini-T, CDR-Life, and TScan, along with a wealth of investment and partnerships amounting to over $700M, it's time to come together to relish in these breakthroughs, while pouring this energy into expanding TCR treatment potential.

The 6th TCR-Based Therapies Summit returns as the only TCR-specific platform for industry experts to join forces to share the technical insights to transform discovery, translation, R and D, and clinical development for cell- and biologic-based approaches.

Providing an unmatched close-knit collaboration environment created specifically with and for the TCR community to connect, and learn from leaders such as Immunocore, Immatics, Marengo, TScan, Medigene, and BioNTech, in a bid to validate novel target antigens, discover safe, potent and optimized TCRs, boost durability in the solid TME, and delve into clinical data, to deliver to more patient populations and achieve clinical validation.

URLs:

Tickets: https://go.evvnt.com/2781971-2?pid=10008

Brochure: https://go.evvnt.com/2781971-3?pid=10008

Time: 8:00 AM - 4:30 PM

Prices:

Drug Developer Pricing - Conference Only: USD 2999.00,

Drug Developer Pricing - Conference + Workshop Day: USD 4197.00,

Academic and Not-For- Profit Pricing - Conference Only: USD 2599.00,

Academic and Not-For- Profit Pricing - Conference + Workshop Day: USD 3597.00,

Service and Solution Provider Pricing - Conference Only: USD 3699.00,

Service and Solution Provider Pricing - Conference + Workshop Day: USD 5097.00

Speakers: Andrea Mayer-Mokler, Vice President and Global Head of Clinical Sciences, Immatics, Annelise Vuidepot, Chief Technology Officer, Immunocore, Athanasia Dasargyri, Preclinical Pharmacology Expert, CDR-Life, Cagan Gurer, Senior Vice President, Discovery and Preclinical Development, TScan Therapeutics, Cassian Yee, Founder, MongooseBio, Claudia Ouyang, Senior Director, Cell and Gene Therapies, BioNTech, Dolores Schendel, Chief Scientific Officer, Medigene, Felix Lorenz, Co-founder, Chief Executive and Scientific Officer, Captain T Cell, Gary Shapiro, Vice President, Discovery Biology, Affini-T Therapeutics, Gene Uenishi, Associate Director - Discovery, GentiBio, Jacob Hurst, CTO and Co-Founder, Etcembly, Jordan Jarjour, Chief Scientific Officer, Moonlight Bio, Lauren Stopfer, Executive Director, Proteomics and Innovation, Aethon Therapeutics, Lilly Wollman, Chief Executive Officer, Synteny, Luise Weigand, Head Of Research, Zelluna Immunotherapy, Luke Pase, Chief Technology Officer, Anocca, Mark Ng, Senior Scientist, TCR Discovery, Affini-T Therapeutics, Michelle Ols, Vice President and Head Of Cell Therapy, Obsidian Therapeutics, Parameswaran Hari, Chief Development Officer, Obsidian Therapeutics, Peggy Sotiropoulou, Chief Scientific Officer, T-Knife Therapeutics, Petra Mlcochova, Project leader, T-Therapeutics, Rachel Abbott, Chief Executive Officer, Pan Cancer T, Roberto Chiarle, Scientific Founder, ALKemist Bio, Stefan Scherer, Chief Executive Officer, 3T Biosciences, Zhen Su, Chief Executive Officer, Marengo Therapeutics